157 related articles for article (PubMed ID: 35428910)
1. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
Gauci ML; Giustiniani J; Lepelletier C; Garbar C; Thonnart N; Dumaz N; Foussat A; Lebbé C; Bensussan A; Marie-Cardine A
Cancer Immunol Immunother; 2022 Nov; 71(11):2731-2742. PubMed ID: 35428910
[TBL] [Abstract][Full Text] [Related]
2. Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
Scheffges C; Devy J; Giustiniani J; Francois S; Cartier L; Merrouche Y; Foussat A; Potteaux S; Bensussan A; Marie-Cardine A
Breast Cancer Res; 2024 Feb; 26(1):28. PubMed ID: 38360636
[TBL] [Abstract][Full Text] [Related]
3. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.
Ortonne N; Ram-Wolff C; Giustiniani J; Marie-Cardine A; Bagot M; Mecheri S; Bensussan A
J Invest Dermatol; 2011 Apr; 131(4):916-24. PubMed ID: 21191401
[TBL] [Abstract][Full Text] [Related]
4. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
5. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
Giustiniani J; Bensussan A; Marie-Cardine A
J Immunol; 2009 Jan; 182(1):63-71. PubMed ID: 19109136
[TBL] [Abstract][Full Text] [Related]
7. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
Giustiniani J; Marie-Cardine A; Bensussan A
J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
[TBL] [Abstract][Full Text] [Related]
8. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
[TBL] [Abstract][Full Text] [Related]
9. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.
Rabot M; El Costa H; Polgar B; Marie-Cardine A; Aguerre-Girr M; Barakonyi A; Valitutti S; Bensussan A; Le Bouteiller P
Int Immunol; 2007 Apr; 19(4):401-9. PubMed ID: 17307798
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
[TBL] [Abstract][Full Text] [Related]
11. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
12. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
[TBL] [Abstract][Full Text] [Related]
13. CD160 Promotes NK Cell Functions by Upregulating Glucose Metabolism and Negatively Correlates With HIV Disease Progression.
Sun Z; Li Y; Zhang Z; Fu Y; Han X; Hu Q; Ding H; Shang H; Jiang Y
Front Immunol; 2022; 13():854432. PubMed ID: 36110864
[TBL] [Abstract][Full Text] [Related]
14. CD160 is essential for NK-mediated IFN-γ production.
Tu TC; Brown NK; Kim TJ; Wroblewska J; Yang X; Guo X; Lee SH; Kumar V; Lee KM; Fu YX
J Exp Med; 2015 Mar; 212(3):415-29. PubMed ID: 25711213
[TBL] [Abstract][Full Text] [Related]
15. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
Barakonyi A; Rabot M; Marie-Cardine A; Aguerre-Girr M; Polgar B; Schiavon V; Bensussan A; Le Bouteiller P
J Immunol; 2004 Nov; 173(9):5349-54. PubMed ID: 15494480
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
17. CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.
Liu FT; Giustiniani J; Farren T; Jia L; Bensussan A; Gribben JG; Agrawal SG
Blood; 2010 Apr; 115(15):3079-88. PubMed ID: 20164468
[TBL] [Abstract][Full Text] [Related]
18. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.
Nikolova M; Marie-Cardine A; Boumsell L; Bensussan A
Int Immunol; 2002 May; 14(5):445-51. PubMed ID: 11978774
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
Malissen N; Grob JJ
Drugs; 2018 Aug; 78(12):1197-1209. PubMed ID: 30097888
[TBL] [Abstract][Full Text] [Related]
20. CD160: a unique activating NK cell receptor.
Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
